首页> 美国卫生研究院文献>Environmental Health Perspectives >Dioxin Revisited: Developments Since the 1997 IARC Classification of Dioxin as a Human Carcinogen
【2h】

Dioxin Revisited: Developments Since the 1997 IARC Classification of Dioxin as a Human Carcinogen

机译:重审二恶英:自1997年IARC将二恶英列为人类致癌物以来的发展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In 1997 the International Agency for Research on Cancer (IARC) classified 2,3,7,8-tetra-chlorodibenzo-p-dioxin (TCDD; the most potent dioxin congener) as a group 1 carcinogen based on limited evidence in humans, sufficient evidence in experimental animals, and extensive mechanistic information indicating that TCDD acts through a mechanism involving the aryl hydrocarbon receptor (AhR), which is present in both humans and animals. The judgment of limited evidence in humans was based primarily on an elevation of all cancers combined in four industrial cohorts. The group 1 classification has been somewhat controversial and has been challenged in the literature in recent years. In this article we review the epidemiologic and mechanistic evidence that has emerged since 1997. New epidemiologic evidence consists primarily of positive exposure–response analyses in several of the industrial cohorts, as well as evidence of excesses of several specific cancers in the Seveso accident cohort. There are also new data regarding how the AhR functions in mediating the carcinogenic response to TCDD. The new evidence generally supports the 1997 IARC classification.
机译:根据人类有限的证据,1997年国际癌症研究机构(IARC)将2,3,7,8-四氯二苯并-对-二恶英(TCDD;最有力的二恶英同源物)归类为第1类致癌物。实验动物的证据以及广泛的机理信息表明TCDD通过涉及芳烃受体(AhR)的机制起作用,该机制存在于人和动物中。对人类有限证据的判断主要基于四个工业队列中所有癌症的合并升高。第1组分类在某种程度上引起争议,并且近年来在文献中受到挑战。在本文中,我们回顾了自1997年以来出现的流行病学和机理学证据。新的流行病学证据主要包括多个工业队列中的阳性暴露-反应分析,以及Seveso事故队列中几种特定癌症过量的证据。也有关于AhR如何介导TCDD致癌反应的新数据。新证据总体上支持1997年IARC分类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号